Cite
HARVARD Citation
Bauman, J. et al. (n.d.). 798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update. Journal for immunotherapy of cancer. p. A846. [Online].